Date: 2013-07-01
Type of information: Collaboration agreement
Compound: PharmacoMDx epigenetic technologies and products
Company: MDX Health (Belgium) - Summit Pharmaceuticals International Corporation (SPI), a subsidiary of Sumitomo Corporation (Japan)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On July 1, 2013, MDxHealth, a belgian molecular diagnostic company that develops and commercializes epigenetic tests to support the diagnosis and treatment of cancer patients, has announced the signing of a partnership with Summit Pharmaceuticals International Corporation (SPI) a subsidiary of Sumitomo Corporation to gain access to the Japanese market with its pharmaco molecular diagnostic (PharmacoMDx) epigenetic technologies and products. Expanding upon MDxHealth\'s PharmacoMDx program, the partnership aims to provide companion diagnostic solutions, or theranostics, to pharmaceutical companies in the Japanese market.
Financial terms: No financial terms have been disclosed.
Latest news:
